BE-102 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

Be Biopharma reports positive preclinical data for BE-102 in Hypophosphatasia

Read More

4 minute read

Pharma Industry News

Be Biopharma reports positive preclinical data for BE-102 in hypophosphatasia

Be Biopharma shares preclinical results for BE-102, a B cell medicine in development for treating hypophosphatasia. Read about its novel approach.

byPallavi Madhiraju

May 18, 2025

web analytics